Iporel

Clonidine Hydrochloride, the active ingredient in Iporel, is an alpha‑2 adrenergic agonist presented as an oral tablet for oral use. It is employed to lower elevated blood pressure, to manage symptoms of attention‑deficit hyperactivity disorder, and to ease withdrawal manifestations in dependent patients.

GNH USA supplies Iporel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Clonidine is an alpha‑2 adrenergic agonist used in several cardiovascular and neuro‑behavioral conditions.

- Hypertension: reduces systolic and diastolic blood pressure by decreasing sympathetic outflow, useful in essential hypertension management. - Attention deficit hyperactivity disorder (ADHD): improves attention and reduces hyperactivity as an adjunctive therapy in patients who respond inadequately to stimulants. - Opioid withdrawal: mitigates autonomic symptoms such as sweating, tachycardia, and anxiety during detoxification from opioids. - Tobacco cessation: assists in reducing withdrawal symptoms and cravings in nicotine dependence.

Clonidine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dry mouth: reduced salivary secretion causing throat discomfort. - Sedation: feeling of drowsiness or fatigue. - Dizziness: light‑headed sensation, especially when standing. - Constipation: slowed gastrointestinal motility. - Headache: mild to moderate pain. - Fatigue: overall lack of energy.

Serious or Rare Side Effects: - Severe hypotension: dangerously low blood pressure requiring medical attention. - Bradycardia or heart block: markedly slow heart rate or conduction abnormalities. - Depression or hallucinations: mood changes or perceptual disturbances. - Allergic reactions: rash, swelling, or anaphylaxis. - Syncope: sudden loss of consciousness. - Renal impairment: worsening kidney function in susceptible individuals.

When prescribing clonidine, clinicians should observe several safety measures to minimize risk.

- Blood pressure monitoring: check blood pressure regularly after initiation and dose changes. - Dose adjustment in renal impairment: reduce dose in patients with reduced kidney function. - Caution in depression: monitor for worsening mood or suicidal thoughts. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Contraindication: hypersensitivity to clonidine or any component of the formulation. - Store at room temperature: keep in original container, protect from moisture and light.

Clonidine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Beta‑blockers: combined use may cause excessive bradycardia and hypotension. - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of profound blood pressure reduction. - Central nervous system depressants (e.g., opioids, benzodiazepines): may enhance sedation and respiratory depression. - MAO inhibitors: can precipitate severe hypotension.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase clonidine plasma levels. - Alcohol: can potentiate sedative effects and dizziness. - Tricyclic antidepressants: additive hypotensive effect, monitor blood pressure.